These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27070264)

  • 41. Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells.
    Hu C; Li L
    Regen Med; 2016 Jan; 11(1):105-32. PubMed ID: 26679838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Granulosa cell-derived induced pluripotent stem cells exhibit pro-trophoblastic differentiation potential.
    Chuang CY; Huang MC; Chen HF; Tseng LH; Yu CY; Stone L; Huang HP; Ho HN; Kuo HC
    Stem Cell Res Ther; 2015 Feb; 6(1):14. PubMed ID: 25889179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.
    Kim JJ; Rai R
    Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inducing goat pluripotent stem cells with four transcription factor mRNAs that activate endogenous promoters.
    Chen H; Zuo Q; Wang Y; Song J; Yang H; Zhang Y; Li B
    BMC Biotechnol; 2017 Feb; 17(1):11. PubMed ID: 28193206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epigenetic regulation of somatic cell reprogramming.
    Wang Y; Bi Y; Gao S
    Curr Opin Genet Dev; 2017 Oct; 46():156-163. PubMed ID: 28823984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induced pluripotent stem cell technology for dissecting the cancer epigenome.
    Semi K; Yamada Y
    Cancer Sci; 2015 Oct; 106(10):1251-6. PubMed ID: 26224327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Environmental epigenetic modifications and reprogramming-recalcitrant genes.
    Sakurada K
    Stem Cell Res; 2010 May; 4(3):157-64. PubMed ID: 20167552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cellular Reprogramming Using Protein and Cell-Penetrating Peptides.
    Seo BJ; Hong YJ; Do JT
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolome Profiling of Partial and Fully Reprogrammed Induced Pluripotent Stem Cells.
    Park SJ; Lee SA; Prasain N; Bae D; Kang H; Ha T; Kim JS; Hong KS; Mantel C; Moon SH; Broxmeyer HE; Lee MR
    Stem Cells Dev; 2017 May; 26(10):734-742. PubMed ID: 28346802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolution of induced pluripotent stem cell technology.
    Zhou H; Ding S
    Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incomplete cellular reprogramming of colorectal cancer cells elicits an epithelial/mesenchymal hybrid phenotype.
    Hiew MSY; Cheng HP; Huang CJ; Chong KY; Cheong SK; Choo KB; Kamarul T
    J Biomed Sci; 2018 Jul; 25(1):57. PubMed ID: 30025541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of the early and late responder genes during the generation of induced pluripotent stem cells from mouse fibroblasts.
    Park J; Kwon YW; Ham S; Hong CP; Seo S; Choe MK; Shin SI; Lee CS; Kim HS; Roh TY
    PLoS One; 2017; 12(2):e0171300. PubMed ID: 28152015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T-cell factor 3 (Tcf3) deletion increases somatic cell reprogramming by inducing epigenome modifications.
    Lluis F; Ombrato L; Pedone E; Pepe S; Merrill BJ; Cosma MP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11912-7. PubMed ID: 21730189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).
    Singh VK; Kumar N; Kalsan M; Saini A; Chandra R
    J Stem Cells; 2015; 10(1):43-62. PubMed ID: 26665937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system.
    Drozd AM; Walczak MP; Piaskowski S; Stoczynska-Fidelus E; Rieske P; Grzela DP
    Stem Cell Res Ther; 2015 Jun; 6(1):122. PubMed ID: 26088261
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The causal relationship between epigenetic abnormality and cancer development: in vivo reprogramming and its future application.
    Yamada Y; Yamada Y
    Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(6):235-247. PubMed ID: 29887568
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epigenetics of cell fate reprogramming and its implications for neurological disorders modelling.
    Grzybek M; Golonko A; Walczak M; Lisowski P
    Neurobiol Dis; 2017 Mar; 99():84-120. PubMed ID: 27890672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-efficiency generation of induced pluripotent mesenchymal stem cells from human dermal fibroblasts using recombinant proteins.
    Chen F; Zhang G; Yu L; Feng Y; Li X; Zhang Z; Wang Y; Sun D; Pradhan S
    Stem Cell Res Ther; 2016 Jul; 7(1):99. PubMed ID: 27473118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications.
    Sadahiro T; Yamanaka S; Ieda M
    Circ Res; 2015 Apr; 116(8):1378-91. PubMed ID: 25858064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New windows to enhance direct reprogramming of somatic cells towards induced pluripotent stem cells.
    Nakhaei-Rad S; Bahrami AR; Mirahmadi M; Matin MM
    Biochem Cell Biol; 2012 Apr; 90(2):115-23. PubMed ID: 22166043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.